Clinical Trials in Beijing, China
1,912 recruiting
Showing 1–20 of 3,550 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health30 enrolled21 locationsNCT07547553
Recruiting
Not Applicable
The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery
hernia repairLaparoscopic CholecystectomyLoxoprofen Sodium Patch+2 more
Beijing Tiantan Hospital134 enrolled2 locationsNCT07591207
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 2
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting
Phase 3
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
Androgen Deprivation TherapyProstate Cancer (Post Prostatectomy)Prostate Cancer Non-Metastatic+2 more
Sun Yat-sen University372 enrolled13 locationsNCT07477626
Recruiting
Not Applicable
Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery
Video-assisted Thoracoscopic Surgery (VATS)SegmentectomyWedge Resection+3 more
Beijing Tiantan Hospital100 enrolled1 locationNCT07603921
Recruiting
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
Non-cystic Fibrosis Bronchiectasis
AstraZeneca320 enrolled38 locationsNCT07245407
Recruiting
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
AstraZeneca2,100 enrolled14 locationsNCT07404202
Recruiting
Phase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
COVID-19 (SARS-CoV-2) infection
Pfizer2,330 enrolled246 locationsNCT06679140
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled383 locationsNCT07116967
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled428 locationsNCT05980949
Recruiting
Not Applicable
Unipolar Voltage Mapping for Personalized Atrial Fibrillation Ablation
Atrial Fibrillation (AF)
China National Center for Cardiovascular Diseases200 enrolled1 locationNCT07630857
Recruiting
Phase 1Phase 2
Study for AZD4360 in Participants With Advanced Solid Tumours
Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting
Phase 4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Multiple Myeloma
Pfizer80 enrolled33 locationsNCT06057402
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled255 locationsNCT06937229
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-small Cell Lung Cancer
AstraZeneca675 enrolled283 locationsNCT06357533
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled183 locationsNCT06646276
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 2
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
Immunological Non-Responders in People With HIV
Beijing 302 Hospital21 enrolled5 locationsNCT07637877